GlassScriptPhysician profile
Hormoz Ashtyani Asl
NPI 1982634952
$1,223.05
in general payments reported to CMS, 2019-2025
22 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.90 · 2020: $245 · 2021: $331 · 2022: $198 · 2023: $172 · 2024: $34.12 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $228.76 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Philips North America LLC | $139.60 | 2021-2024 | (Ak6) Vest Therapy |
| Jazz Pharmaceuticals INC. | $126.02 | 2021-2025 | |
| Gilead Sciences, INC. | $104.32 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $80.78 | 2020-2023 | Acthar |
| Sunovion Pharmaceuticals INC. | $68.17 | 2020-2021 | |
| Inspire Medical Systems, INC. | $65.87 | 2023 | Inspire |
| Mylan Specialty L.P. | $51.80 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.34 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $38.07 | 2021 | |
| Verona Pharma, INC. | $37.00 | 2025 | Ohtuvayre |
| Pfizer INC. | $34.37 | 2025 | |
| Ani Pharmaceuticals, INC. | $33.56 | 2022 | |
| Genzyme Corporation | $31.90 | 2024-2025 | |
| Harmony Biosciences LLC | $27.14 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.83 | 2025 | Zepbound |
| Azurity Pharmaceuticals, INC. | $17.57 | 2025 | Alvesco |
| Actelion Pharmaceuticals US, INC. | $16.29 | 2025 | Opsumit |
| Advanced Respiratory, INC | $15.36 | 2021 | |
| Electromed, INC. | $14.57 | 2021 | |
| Axsome Therapeutics, INC. | $13.99 | 2023 | Sunosi |
| Merck Sharp & Dohme LLC | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hormoz Ashtyani Asl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.